Navigation Links
Women & Infants participating in study of treatment of common viral infection in pregnancy
Date:4/23/2012

Women & Infants Hospital of Rhode Island, through its participation in the Maternal-Fetal Medicine Units Network, has been named the lead center in a 14-site, $25 million study of cytomegalovirus (CMV), the most common infection during pregnancy. Researchers want to see whether giving recently infected pregnant women antibodies against CMV lowers the rate of CMV infection in their babies. This study is funded by the National Institute of Health's Eunice Kennedy Shriver National Institute of Child Health and Human Development.

Principal investigator is Brenna Anderson, MD, of the Division of Maternal-Fetal Medicine and the Integrated Program for High-Risk Pregnancy at Women & Infants Hospital and assistant professor of obstetrics and gynecology at The Warren Alpert Medical School of Brown University.

Dr. Anderson said, "Each year in the US, CMV infection affects more infants than Down syndrome and spina bifida combined. Yet until recently we have not been able to efficiently screen for it. Now that we can, we are in a position to test promising treatments."

CMV is a common virus spread like a cold or the flu. Approximately 1% of pregnant women will be infected with CMV for the first time, which results in a 40% chance that the fetus will also be infected. Fetuses who are infected with CMV are more likely to be born earlier than expected and develop problems such as hearing loss and learning disabilities.

The study will screen more than 150,000 women for evidence of primary CMV infection and randomize those who are positive to CMV hyperimmune globulin or placebo in an effort to decrease the risk of congenital CMV. This will be among the biggest trials done by the Maternal-Fetal Medicine Units Network in their 20+ year history.

Pregnant women with a single fetus who have not yet reached the 24th week of pregnancy are eligible to participate in this study. A small amount of additional blood will be taken from participants in conjunction with routinely scheduled prenatal blood testing (that is, the screening will minimize needle sticks).

"Screening will show a woman if she has been infected with CMV while pregnant, and she may then be eligible for the randomized treatment trial," said Dr. Anderson.


'/>"/>
Contact: Amy Blustein
ablustein@wihri.org
401-681-2822
Women & Infants Hospital
Source:Eurekalert

Related biology news :

1. Women do not recover their muscle strength as fast as men
2. Brown University and Women & Infants Hospital expand national childrens study to Bristol County
3. Vitamin K does not stem BMD decline in postmenopausal women with osteopenia
4. Study: Elderly Women can increase strength but still risk falls
5. Pregnant women consuming flaxseed oil have high risk of premature birth
6. 17th Annual Congress on Womens Health convenes
7. Pregnant women with asthma can be more confident about some medicines
8. Men are red, women are green, Brown researcher finds
9. Statin warning for pregnant women
10. Long-term use of diabetes drugs by women significantly increases risk of fractures
11. Women double fruit, veggie intake with switch to Mediterranean diet plan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2017)... NEW YORK , Feb. 7, 2017 Report ... ... and should reach $11.4 billion by 2021, growing at a ... Report Includes - An overview of the global markets for ... from 2015, estimates for 2016, and projections of compound annual ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/3/2017)... -- A new independent identity strategy consultancy firm announces ... Designed to fill a critical niche in technical and ... Mark Crego and Janice Kephart ... expertise that span federal governments, the 9/11 Commission, private ... expertise has a common theme born from a shared ...
Breaking Biology News(10 mins):
(Date:2/22/2017)... LEAWOOD, Kan. , Feb. 22, 2017  Aratana Therapeutics, ... licensing, development and commercialization of innovative biopharmaceutical products for companion ... 14, 2017 at 8:30 a.m. ET to discuss financial results ... 2016. Interested participants and investors may access ... dial-in: ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Park ... free AFM Luncheon for all SPIE attendees and Park customers ... just one block from the San Jose Convention Center. The luncheon will feature ...
(Date:2/22/2017)... Scientists propose in Nature blocking ... Gaucher and maybe other lysosomal storage diseases as a ... current therapies. An international research team led ... also included investigators from the University of Lübeck in ... 22. The study was conducted in mouse models of ...
(Date:2/22/2017)... Toronto, ON (PRWEB) , ... February 22, 2017 ... ... focused on discovery and development of precision treatments for neurodegenerative diseases, today announced ... trials validate the ProMIS approach.” This is one of a series of commentaries ...
Breaking Biology Technology: